NCT01541085View on ClinicalTrials.gov

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Human Immunodeficiency Virus; HIV
Interventions
DRUG

Darunavir/Ritonavir (DRV/r)

Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen

DRUG

Efavirenz (EFV)

Efavirenz (EFV) + Tenofovir/Emtricitabina regimen

All Listed Sponsors
lead

Janssen-Cilag S.p.A.

INDUSTRY

NCT01541085 - An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART | Biotech Hunter | Biotech Hunter